Table 1.
Bivariate Analysis of Predictors of Financial Toxicity
| Variable | Distributiona | COST Score Mean (SD) | Pb |
|---|---|---|---|
| Age (years) | 64.1 (43.1 – 85.4) | 0.30 (0.02) | |
| Sex | 0.29 | ||
| Male | 56 (89%) | 26.1 (11.2) | |
| Female | 7 (11%) | 20.8 (15.6) | |
| Race/Ethnicity | 0.83 | ||
| White | 58 (92%) | 25.5 (12.2) | |
| Non-White/Refused | 5 (8%) | 26.6 (4.2) | |
| Marital Status | 0.57 | ||
| Married/Domestic Partnership | 36 (57%) | 26.3 (13.1) | |
| Non-Married | 27 (43%) | 24.6 (9.8) | |
| Baseline Employment | 0.08 | ||
| Employed | 29 (46%) | 23.7 (11.8) | |
| Retired | 22 (35%) | 30.2 (10.3) | |
| Disability/Unemployed | 12 (19%) | 21.9 (12.0) | |
| Primary Insurance Type | 0.72 | ||
| VA (+/−supplemental) | 27 (43%) | 24.3 (9.5) | |
| Private (+/−Medicare Part A/B) | 28 (44%) | 26.8 (11.5) | |
| Medicaid | 8 (13%) | 24.4 (11.5) | |
| Radiation Facility | 0.54 | ||
| Comprehensive Cancer Center | 36 (57%) | 26.3 (12.9) | |
| Veterans Affairs Hospital | 27 (43%) | 24.3 (9.5) | |
| Distance to Radiation Facility (miles) | 0.11 | ||
| Median | 58.4 (0 – 510.0) | ||
| <50 | 26 (41%) | 29.1 (9.8) | |
| 50 –99.9 | 21 (33%) | 24.7 (13.0) | |
| ≥100 | 16 (25%) | 21.3 (11.5) | |
| Household Income ($k/year)c | 0.01 | ||
| Median | 50.8 (37.6 – 79.4) | ||
| <50 | 28 (44%) | 21.3 (12.7) | |
| ≥50 | 35 (56%) | 29.0 (9.7) | |
| Primary Site | 0.67 | ||
| Larynx (including Hypopharynx) | 19 (30%) | 24.7 (13.0) | |
| Oropharynx | 22 (35%) | 24.6 (12.7) | |
| Nasopharynx | 4 (6%) | 26.0 (9.4) | |
| Oral cavity | 6 (10%) | 33.0 (11.5) | |
| Other (including Unknown Primary) | 12 (19%) | 25.0 (8.9) | |
| Human Papillomavirus Statusd | 0.65 | ||
| Positive | 21 (33%) | 24.6 (12.8) | |
| Negative or Unknown | 8 (11%) | 26.1 (11.2) | |
| AJCC 7th Edition Stage | 0.37 | ||
| I | 5 (8%) | 25.7 (22.4) | |
| II | 4 (6%) | 33.7 (5.5) | |
| III | 10 (16%) | 20.8 (9.6) | |
| IV (Non-metastatic) | 44 (70%) | 26.0 (11.5) | |
| # Tobacco Pack Years (years) | 20 (0 – 110) | 0.06 (0.66) | |
| Radiation Intent | 0.81 | ||
| Definitive | 44 (70%) | 25.1 (11.9) | |
| Post-operative | 18 (29%) | 26.2 (11.7) | |
| Palliative | 1 (2%) | 32 | |
| Concurrent Systemic Therapye | 0.36 | ||
| Yes | 40 (63%) | 24.6 (11.4) | |
| No | 23 (37%) | 27.6 (12.5) | |
| Clinical Trial Enrollment | 0.20 | ||
| Yes | 9 (14%) | 21.0 (12.9) | |
| No | 54 (86%) | 26.4 (11.4) | |
| Radiation | |||
| Total Dose (Gray) | 70 (50 – 70) | −0.09 (0.51) | |
| # Fractions | 35 (20 – 35) | −0.13 (0.33) | |
| Time from End of Radiation to Survey (months) | 4 (0.5 – 12) | 0.21 (0.12) |
Abbreviations: AJCC=American Joint Committee on Cancer; SD=standard deviation
a
Data presented as n (%) or Median (Range).
b
p-values derived from linear regression or rho (p-value) from Pearson Correlation (continuous variables).
c
Median household income by County (2016 U.S. Census data)
d
Reported for patients with oropharynx, nasopharynx, or unknown primaries only (n =29)
e
Including chemotherapy, cetuximab, or immunotherapy